The results show that MTMZM can effectively relieve eczema skin lesions, which may be related to the inhibition of p38/NF-κB and JAK1-STAT6 pathways, while clinical translation requires further validation. This evidence concerns the gene JAK1 and Eczematoid dermatitis.